This is a covid-19/coronavirus related contract action for the following testing services: 4-in-1 LC-MS/MS method development, method qualification, sample analysis, and sample RE-analysis for…
Ended Purchase Order Awarded Last action
- Contract number
- 75N95021P00013
- Awardee
-
QPS LLC UEI P2F8FYL11D41
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $34,692
Award facts
- Opportunity
-
- Bioanalytical Assay Development and Concentration Determination for Remdesivir, GS-441524, GS-441524 Mono- and Tri-Phosphates in Cell Lysates Solicitation · 75N95021Q00005 · Posted Oct 29, 2020
- Contract value 100% obligated
- $34,692.39 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Newark, DE, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$57,208 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $91,900 |
About this award
The National Institute on Drug Abuse awarded a purchase order to QPS LLC for $34,692.39 on November 9, 2020, for COVID-19-related testing services. Work is performed in Newark, Delaware. The order covers 4-in-1 LC-MS/MS method development, method qualification, sample analysis, and sample re-analysis for remdesivir, GS-441524, remdesivir monophosphate, and related compounds. Ultimate completion is March 13, 2027. The procurement originated from a solicitation posted October 29, 2020, with a due date of November 4, 2020. The purchase order was issued to de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) ahead of the September 30, 2026 close of period of availability.
Description
This is a covid-19/coronavirus related contract action for the following testing services: 4-in-1 LC-MS/MS method development, method qualification, sample analysis, and sample RE-analysis for remdesivir, GS-441524, remdesivir monophosphate and remde
Quick answers
Who was awarded contract 75N95021P00013?
75N95021P00013 was awarded to QPS LLC by National Institute on Drug Abuse (National Institutes of Health) on November 9, 2020.
How much is contract 75N95021P00013 worth?
The government has obligated $34,692 on 75N95021P00013.
Was contract 75N95021P00013 competed?
The extent of competition for 75N95021P00013 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award